Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | RXRG | P48443 | 1/20 | 0.45 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17062167 | 0.85 | IDO1 (0.41) | SLC13A3IDO1MEN1PLA2G1BCYP1A2 | |
| SCHEMBL265486 | 0.84 | IDO1 (0.52) | RXRARXRBRXRGPRKCAPRKCD | |
| SCHEMBL15516391 | 0.79 | SLC13A3 (0.40) | SLC13A3IDO1MEN1PLA2G1BCYP1A2 | |
| SCHEMBL30302522 | 0.79 | IDO1 (0.44) | SLC13A3IDO1MEN1PLA2G1BCYP1A2 | |
| SCHEMBL1229494 | 0.79 | IDO1 (0.39) | SLC13A3IDO1MEN1PLA2G1BCYP1A2 | |
| SCHEMBL257077 | 0.79 | RAPGEF4 (0.41) | SLC13A3IDO1MEN1PLA2G1BCYP1A2 | |
| SCHEMBL19294284 | 0.79 | GABRA1 (0.38) | RXRARXRBRXRGMEN1CYP1A2 | |
| SCHEMBL5730059 | 0.79 | IDO1 (0.44) | SLC13A3IDO1MEN1PLA2G1BCYP1A2 | |
| SCHEMBL1912907 | 0.79 | IDO1 (0.39) | SLC13A3IDO1MEN1PLA2G1BCYP1A2 | |
| SCHEMBL27401833 | 0.79 | SLC13A3 (0.37) | SLC13A3IDO1MEN1PLA2G1BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118908815-A | Preparation method of 1- [ 3-chloro-5- (trifluoromethyl) phenyl ] -2, 2-trifluoro-ethanone | 河北嘉伟生物科技有限公司 | 2024-11-08 | — | — | CN | claimed |
| CN-118908815-A | Preparation method of 1- [ 3-chloro-5- (trifluoromethyl) phenyl ] -2, 2-trifluoro-ethanone | 河北嘉伟生物科技有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-20200157088-A1 | BENZENE FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2020-05-21 | — | — | US | disclosed |
| US-10633384-B2 | Diazaspirocycloalkane and azaspirocycloalkane | HOFFMANN-LA ROCHE INC. (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-01-31 | — | — | US | disclosed |
| US-10125098-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180265465-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-09-20 | — | — | US | disclosed |
| US-20100087434-A1 | NK-1 and Serotonin Transporter Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-08 | — | — | US | disclosed |
| US-20100087434-A1 | NK-1 and Serotonin Transporter Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-08 | — | — | US | disclosed |
| US-20100087434-A1 | NK-1 and Serotonin Transporter Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-08 | — | — | US | disclosed |
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
| US-20070249607-A1 | NK-1 AND SEROTONIN TRANSPORTER INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| US-20070249607-A1 | NK-1 AND SEROTONIN TRANSPORTER INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| US-20070249607-A1 | NK-1 AND SEROTONIN TRANSPORTER INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| WO-2007121389-A2 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AS NK-I AND SEROTONIN TRANSPORTER INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007121389-A2 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AS NK-I AND SEROTONIN TRANSPORTER INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | RXRA 24/4885RXRB 137/4885RXRG 185/4885 |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | RXRA 24/4885RXRB 137/4885RXRG 185/4885 |
| US-20180265465-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | RXRA 24/4885RXRB 137/4885RXRG 185/4885 |
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | RXRA 3021/4885RXRB 2702/4885RXRG 2815/4885 |
| US-10633384-B2 | Diazaspirocycloalkane and azaspirocycloalkane | ENPP2, DAPK1, DAPK2 | RXRA 1082/4885RXRB 1197/4885RXRG 998/4885 |
| US-20100087434-A1 | NK-1 and Serotonin Transporter Inhibitors | SLC6A4, TPH1, SLC6A2 | RXRA 4770/4885RXRB 4630/4885RXRG 4705/4885 |
| US-20200157088-A1 | BENZENE FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | NR2C2, NR0B2, NR0B1 | RXRA 131/4885RXRB 20/4885RXRG 155/4885 |
| US-10125098-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | RXRA 24/4885RXRB 137/4885RXRG 185/4885 |
| US-20070249607-A1 | NK-1 AND SEROTONIN TRANSPORTER INHIBITORS | SLC6A4, TPH1, SLC6A2 | RXRA 4770/4885RXRB 4630/4885RXRG 4705/4885 |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | RXRA 24/4885RXRB 137/4885RXRG 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.